CareRx Corp. Stock
€1.33
Your prediction
CareRx Corp. Stock
Pros and Cons of CareRx Corp. in the next few years
Pros
Cons
Performance of CareRx Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CareRx Corp. | - | -3.623% | 0.758% | -19.394% | 33.668% | -61.337% | -65.183% |
| Sienna Senior Living Inc | -1.720% | -2.247% | 0.578% | 20.833% | 14.474% | -10.769% | -27.258% |
| Eifelhoehen-Klinik | -10.000% | 25.000% | 3.448% | -37.500% | 0.000% | -62.121% | -56.647% |
| Elan Corp. | -1.830% | -5.217% | -0.909% | -18.045% | -21.583% | -47.596% | -59.624% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.CareRx Corporation, a prominent player in the Healthcare Providers & Services industry, exhibits mixed financials based on its performance in recent years. Although the company demonstrates a steady increment in total revenue, their net income consistently suffers from most of their financial results.
Rising Revenue: CareRx has witnessed a consistent surge in total revenue across all three years under consideration - from CAD 162.2 million in 2020 to CAD 262.6 million in 2021 and CAD 381.7 million in 2022. This growth suggests that the company is successful in expanding its business and increasing sales.
Improving Gross Profit: Another positive takeaway is the continuous growth in gross profit - from CAD 47 million in 2020 to CAD 75.3 million in 2021 and finally, CAD 109.9 million in 2022. The higher gross profit signifies that the company's operations are becoming more cost-efficient, allowing it to generate better margins.